This is an entirely free service. No payments are to be made. Also send me The Ultimate Guide to Profiting From Derivatives and sign me up for Profit Hunter,a free newsletter that focuses on identifying short term money making opportunities.Download NowSubscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.

Majority of the food & tobacco companies are trading positive with Tata Global Beverages and Agro Tech Foods being the biggest gainers. As per a leading daily, biscuit companies are increasingly launching premium products to capitalize on the growing consumer preference for better quality biscuits. Parle Products is upping its ante in both cookie and cream biscuit segments through launches such as Milano chocolate chip cookies, Golden Arcs, Monaco Cream, Happy Cream and Black Bourbon. Britannia, which is a strong player in the cookie segment, has launched three cookies in the last three months namely Tiger Butter Krunch, Nutrichoice Heavens and Good Day Chunkies. ITC, on the other hand, is a large player in creams and has been widening its cream portfolio under the Dark Fantasy Brand. Reportedly, Parle Products is the biggest player in the combined cookie & cream biscuit market with a 30% market share followed by Britannia and ITC having shares of 24% and 15%, respectively. However both Britannia and ITC have been working towards gaining shares in segments where they have been lagging. While Britannia is trading up 0.3%, ITC is trading down 0.9%.

Most of the domestic pharma stocks are trading in the green led by Panacea Biotech and Natco Pharma. As per a leading financial daily, Cadila Healthcare has become the first company to launch biosimilar version of Adalimumab drug. The drug marketed under the brand name Exemptia will be used in the treatment of auto immune disorders such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis and Ankylosing Spondylytis. The innovator drug is still under patent in the US and other markets. The patent will expire in 2019 in the US and earlier in the other markets. The drug would be priced at around 20% of what it is priced in the US where a vial costs around $1,000. The company expects to garner Rs 1 bn in revenues from the product in three years. Cadila Healthcare stock is trading up by 1.3%.

OTHER USEFUL LINKS

MARKET STATS

ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.